Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …

Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial
myocardial collagen network that occur in response to cardiac ischaemic insults, systemic …

Disease models are essential for understanding cardiovascular disease pathogenesis and
developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology …

Background: The local inflammatory tissue response after acute myocardial infarction (MI)
determines subsequent healing. Systemic interaction may induce neuroinflammation as a …

Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

Cell therapy treatment of myocardial infarction (MI) is mediated, in part, by exosomes
secreted from transplanted cells. Thus, we compared the efficacy of treatment with a mixture …

Pluripotent stem-cell-derived cardiomyocytes (PSC-CMs) provide an unprecedented
opportunity to study human heart development and disease, but they are functionally and …

Heart failure with preserved ejection fraction (HFpEF) is characterized by signs and
symptoms of heart failure in the presence of a normal left ventricular ejection fraction …

Simple Summary We review the value of large animal models for improving the translation of
biomedical research for human application, focusing primarily on sheep. Abstract An …